How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Pan Tumor Rollover Study

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Nivolumab (drug), Ipilimumab (drug), Cabozantinib (drug), Trametinib (drug)
How long the study runs: Study runs about 120 months (dates as stated)
About the drug or intervention: Nivolumab — drug: Specified dose on specified days · Ipilimumab — drug: Specified dose on specified days · Cabozantinib — drug: Specified dose on specified days · Trametinib — drug: Specified dose on specified days · Relatlimab — drug: Specified dose on specified days · Nivolumab + Relatlimab — drug: Specified dose on specified days · Capecitabine — drug: Specified dose on specified days · Bevacizumab — drug: Specified dose on specified days · Temozolomide — drug: Specified dose on specified days · Rucaparib — drug: Specified dose on specified days · Daratumumab — drug: Specified dose on specified days · Regorafinib — drug: Specified dose on specified days · Leucovorin — drug: Specified dose on specified days · Fluorouracil — drug: Specified dose on specified days · Oxaliplatin — drug: Specified dose on specified days · Enzalutamide — drug: Specified dose on specified days · Sunitinib — drug: Specified dose on specified days · Pemetrexed — drug: Specified dose on specified days · Pembrolizumab — drug: Specified dose on specified days
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 1,500
Started: 2019-08-09
Last checked: 2026-09

Plain English Summary

What is this study?

• Testing a new treatment for cancer
• Phase2 - 1,500 participants
• Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types

Who can take part?

• Ages 18 Years and over
• Diagnosed with cancer

Where?

• London - Local Institution - 0141
• London - University College Hospital
• London - Local Institution - 0272
• London - Local Institution - 0086
• +6 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Cancer

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

What the study is looking for

✓Inclusion Criteria
✓Signed Written agreement to take part.
✓Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per...
✓On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as...
✓WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception...

See the full criteria

Inclusion Criteria * Signed Written Informed Consent. * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF. Exclusion Criteria * Participant is not eligible for study treatment per the Parent Study eligibility criteria. * Participants not receiving clinical benefit as assessed by the Investigator. * Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant. * Other protocol-defined Inclusion/Exclusion Criteria apply

Where Is This Study? (10 UK sites)

Local Institution - 0141

London N18 1QX, United Kingdom

COMPLETED

University College Hospital

London NW1 2PG, United Kingdom

Recruiting

Site contact (verified)

Paul Mulholland, Site 0314+44 20 3456 7890

Local Institution - 0272

London SM2 5PT, United Kingdom

COMPLETED

Local Institution - 0086

London SW3 6JJ, United Kingdom

COMPLETED

Local Institution - 0115

Manchester M20 4BX, United Kingdom

COMPLETED

Local Institution - 0195

Southampton SO16 6YD, United Kingdom

COMPLETED

Local Institution - 0231

Maidstone ME16 9QQ, United Kingdom

WITHDRAWN

Local Institution - 0161

Northwood HA6 2RN, United Kingdom

COMPLETED

Local Institution - 0299

Edinburgh EH4 2XU, United Kingdom

WITHDRAWN

Local Institution - 0259

Glasgow G12 0YN, United Kingdom

WITHDRAWN

How to Get in Touch

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

Sponsor contact

CONTACT

855-907-3286 Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Sponsor contact

CONTACT

Data sourced from ClinicalTrials.gov · Last verified: 2026-09